Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer

NCT01605318 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01605318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01605318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Terminated
Start date
February 12, 2013
Completion date
January 3, 2017
Enrollment
92 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, metastatic colorectal cancer, rectal cancer